| International Session（Workshop）1(JSGE・JSH) |
| Fri. November 1st 15:30 - 17:00 Room 9: Portopia Hotel Main Building Kairaku 3 |
| Application of highly-sensitive HBcrAg assay to guide anti-HBV treatment | |||
| Tetsuya Hosaka1, Fumitaka Suzuki1, Hiromitsu Kumada1 | |||
| 1Department of Hepatology, Toranomon Hospital | |||
|
|||
|
|||
| (Background) HBcrAg is a unique serum marker that reflects intrahepatic cccDNA levels and transcriptional activity of HBV. Recently, a highly-sensitive assay for HBcrAg (iTACT-HBcrAg) has been developed, and its clinical usefulness needs to be clarified. Therefore, we investigated the association between iTACT-HBcrAg and HCC or fibrosis progression. (Method) We enrolled untreated 1821 HBeAg-negative patients with or without cirrhosis who had been followed up for at least 1 year and whose baseline HBcrAg levels could be measured by iTACT-HBcrAg. We evaluated liver fibrosis using the cut-off of APRI score according to new WHO guideline. We categorized the cohort into four groups using HBcrAg levels as following: Group A: <2.1, Group B: 2.1-2.9, Group C: 3.0-3.9, and Group D: ≥4.0. (Results) (1) Baseline iTACT-HBcrAg levels (median) by APRI value showed a trend toward higher HBcrAg with increasing APRI (P-trend <0.001): APRI <0.5: 2.5 log U/mL, 0.5-1.0: 3.0, >1.0: 4.0. (2) Annual HCC incidence rates were 0.7 1000 person-years in group A, 2.5 in group B, 2.4 in group C, and 20.8 in group D. In multivariable Cox regression adjusted for APRI level, age, sex, and HBVDNA level, the hazard ratios for HCC were 4.49 in group B and 5.60 in group C compared to group A. The risk of HCC increased with increasing iTACT-HBcrAg levels. (Conclusion) iTACT-HBcrAg assay may be a useful marker to predict the fibrosis progression or the risk of HCC. It is necessary to consider how iTACT-HBcrAg should be used to guide anti-HBV therapy in the future. |
|||
|
Index Term 1: iTACT-HBcrAg Index Term 2: HCC |
|||
| Page Top | |||